Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.

Valentina Morena, Laura Milazzo, Letizia Oreni, Giovanna Bestetti, Tommaso Fossali, Cinzia Bassoli, Alessandro Torre, Maria Vittoria Cossu, Caterina Minari, Elisabetta Ballone, Andrea Perotti, Davide Mileto, Fosca Niero, Stefania Merli, Antonella Foschi, Stefania Vimercati, Giuliano Rizzardini, Salvatore Sollima, Lucia Bradanini, Laura Galimberti, Riccardo Colombo, Valeria Micheli, Cristina Negri, Anna Lisa Ridolfo, Luca Meroni, Massimo Galli, Spinello Antinori, Mario Corbellino, Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. European Journal of Internal Medicine. ,vol. 76, pp. 36- 42 ,(2020) , 10.1016/J.EJIM.2020.05.011

Farzaneh Dastan, Seyed Alireza Nadji, Ali Saffaei, Payam Tabarsi, Tocilizumab administration in a refractory case of COVID-19. International Journal of Antimicrobial Agents. ,vol. 56, pp. 106043- ,(2020) , 10.1016/J.IJANTIMICAG.2020.106043

Matthew J. Frigault, Sarah Nikiforow, Michael K. Mansour, Zhen-Huan Hu, Mary M. Horowitz, Marcie L. Riches, Peiman Hematti, Cameron J. Turtle, Mei-Jie Zhang, Miguel-Angel Perales, Marcelo C. Pasquini, Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood. ,vol. 136, pp. 137- 139 ,(2020) , 10.1182/BLOOD.2020006216

Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, Anna Maria Marata, Patrizia Popoli, Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Diego Ripamonti, Francesca Binda, Paolo Bonfanti, Nicola Squillace, Francesco Castelli, Maria Lorenza Muiesan, Miriam Lichtner, Carlo Calzetti, Nicola Duccio Salerno, Luigi Atripaldi, Marco Cascella, Massimo Costantini, Giovanni Dolci, Nicola Cosimo Facciolongo, Fiorentino Fraganza, Marco Massari, Vincenzo Montesarchio, Cristina Mussini, Emanuele Alberto Negri, Gerardo Botti, Claudia Cardone, Piera Gargiulo, Adriano Gravina, Clorinda Schettino, Laura Arenare, Paolo Chiodini, Ciro Gallo, Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial medRxiv. ,(2020) , 10.1101/2020.06.01.20119149

Estela Moreno-García, Verónica Rico, Laia Albiach, Daiana Agüero, Juan Ambrosioni, Marta Bodro, Celia Cardozo, Mariana Chumbita, Lorena De la Mora, Nicole García-Pouton, Carolina Garcia-Vidal, Ana González-Cordón, Marta Hernández-Meneses, Alexy Inciarte, Montse Laguno, Lorna Leal, Laura Linares, Irene Macaya, Fernanda Meira, Josep Mensa, Antonio Moreno, Laura Morata, Pedro Puerta-Alcalde, Jhon Rojas, Montse Solá, Berta Torres, Manuel Torres, Adrià Tomé, Pedro Castro, Sara Fernández, Josep Maria Nicolás, Alex Almuedo-Riera, Jose Muñoz, Mariana Jose Fernandez-Pittol, Maria Angeles Marcos, Dolors Soy, José Antonio Martínez, Felipe García, Alex Soriano, Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection medRxiv. ,(2020) , 10.1101/2020.06.05.20113738

Luca Quartuccio, Arianna Sonaglia, Davide Pecori, Maddalena Peghin, Martina Fabris, Carlo Tascini, Salvatore De Vita, Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6. Journal of Medical Virology. ,vol. 92, pp. 2852- 2856 ,(2020) , 10.1002/JMV.26149

Miguel Górgolas Hernández-Mora, Alfonso Cabello Úbeda, Laura Prieto Pérez, Felipe Villar Álvarez, Beatriz Álvarez Álvarez, María Jesús Rodríguez Nieto, Irene Carrillo Acosta, Itziar Fernández Ormaechea, Aws Waleed Mohammed Al-Hayani, Pilar Carballosa, Silvia Calpena Martínez, Farah Ezzine, Marina Castellanos González, Alba Naya, Marta López de las Heras, Marcel José Rodríguez Guzmán, Ana Cordero Guijarro, Antonio Broncano Lavado, Alicia Macías Valcayo, Marta Martín García, Javier Bécares Martínez, Ricardo Fernández Roblas, Miguel Ángel Piris Pinilla, José Fortes Alen, Olga Sánchez Pernaute, Fredeswinda Romero Bueno, Sarah Heili Frades, Germán Peces Barba Romero, COVID-FJD-TEAM, None, Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late medRxiv. ,(2020) , 10.1101/2020.06.13.20130088

Marie Bossert, Julio Badie, Thierry Conrozier, Chaouki Mezher, Anne Lohse, Ana-Maria Bozgan, Souheil Zayet, Vincent Gendrin, Lynda Toko, Timothée Klopfenstein, Ndri Juliette Kadiane-Oussou, Rémy Contreras, Isabelle Mazurier, Aline Charpentier, Pascale Dussert, Marie-Françoise Roux, Julie Kessler, Jean-Charles Balblanc, Pierre-Yves Royer, Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration Clinical and Experimental Rheumatology. ,vol. 38, pp. 742- 747 ,(2020)

Tariq Kewan, Fahrettin Covut, Mohammed J. Al–Jaghbeer, Lori Rose, K.V. Gopalakrishna, Bassel Akbik, Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. EClinicalMedicine. ,vol. 24, pp. 100418- 100418 ,(2020) , 10.1016/J.ECLINM.2020.100418

Giovanni Guaraldi, Marianna Meschiari, Alessandro Cozzi-Lepri, Jovana Milic, Roberto Tonelli, Marianna Menozzi, Erica Franceschini, Gianluca Cuomo, Gabriella Orlando, Vanni Borghi, Antonella Santoro, Margherita Di Gaetano, Cinzia Puzzolante, Federica Carli, Andrea Bedini, Luca Corradi, Riccardo Fantini, Ivana Castaniere, Luca Tabbì, Massimo Girardis, Sara Tedeschi, Maddalena Giannella, Michele Bartoletti, Renato Pascale, Giovanni Dolci, Lucio Brugioni, Antonello Pietrangelo, Andrea Cossarizza, Federico Pea, Enrico Clini, Carlo Salvarani, Marco Massari, Pier Luigi Viale, Cristina Mussini, Tocilizumab in patients with severe COVID-19: a retrospective cohort study The Lancet Rheumatology. ,vol. 2, pp. 1- 11 ,(2020) , 10.1016/S2665-9913(20)30173-9